Navigation Links
XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Date:10/10/2008

WASHINGTON and MENLO PARK, Calif., Oct. 10 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that it plans to present long-term follow-up data from the CUSTOM I, II and III clinical trials next week at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. The CUSTOM clinical trials are prospective studies designed to investigate the safety and efficacy of the Custom NX(R) drug eluting stent (DES) system in treating patients with coronary artery disease.

Pieter R. Stella, MD, Director, Cardiovascular Research, University Medical Centre Utrecht, The Netherlands, and one of the CUSTOM clinical trial investigators, will present the data during a scientific symposium entitled, "The Drug Eluting Stent Summit, Part II," on Monday, October 13, 2008 at 2:54 p.m., eastern time, at the Walter E. Washington Convention Center, Ballroom C, Level 3. The data presentation will be posted on the XTENT website at http://www.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's quarterly report on Form 10-Q for the quarter ended June 30, 2008. This quarterly report was filed with the SEC on August 12, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces First Quarter 2008 Financial Results
5. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
6. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
7. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
8. XTENT Announces European Regulatory Update
9. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MUMBAI , March 23, 2017 ... de Piramal Enterprises Limited, anuncia el nombramiento de ... PPS ofrece una plataforma de servicios integrados completa ... Needleman desempeñará un cargo clave en el crecimiento ... comercial, Needleman será responsable de impulsar todas las ...
(Date:3/23/2017)... 23, 2017  Galmed Pharmaceuticals Ltd. (Nasdaq: ... clinical-stage biopharmaceutical company focused on the development of ... nonalcoholic steatohepatitis, or NASH, and other liver diseases, ... twelve months ended December 31, 2016, and announced new ... demonstrating Aramchol™,s potential direct effect on liver fibrosis. ...
(Date:3/23/2017)... 23, 2017 ReNeuron reported in December ... in chronic stroke patients, despite not meeting the three-month time ... the Action Research Arm Test (ARAT). As a result, the ... controlled clinical study in 2017. Beyond CTX, we expect safety ... 2017 and Phase I data from its critical limb ischaemia ...
Breaking Medicine Technology:
(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
Breaking Medicine News(10 mins):